According to Zacks, “Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. “
Other analysts have also recently issued reports about the stock. Cowen and Company reiterated a buy rating on shares of Blueprint Medicines Corp. in a research note on Tuesday, August 9th. Canaccord Genuity started coverage on shares of Blueprint Medicines Corp. in a research note on Friday, August 5th. They issued a buy rating and a $26.00 price objective for the company. TheStreet upgraded shares of Blueprint Medicines Corp. from a sell rating to a hold rating in a research note on Friday, July 29th. Finally, Wedbush restated an outperform rating and issued a $41.00 price objective on shares of Blueprint Medicines Corp. in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $30.00.
Blueprint Medicines Corp. (NASDAQ:BPMC) opened at 29.75 on Tuesday. The company’s market capitalization is $810.00 million. Blueprint Medicines Corp. has a 52-week low of $13.04 and a 52-week high of $30.90. The stock has a 50 day moving average of $28.13 and a 200-day moving average of $21.91.
Blueprint Medicines Corp. (NASDAQ:BPMC) last posted its earnings results on Tuesday, August 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.03. The firm earned $7.07 million during the quarter, compared to analysts’ expectations of $4.41 million. Blueprint Medicines Corp. had a negative net margin of 284.85% and a negative return on equity of 46.01%. The company’s revenue was up 163.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.81) earnings per share. On average, equities analysts forecast that Blueprint Medicines Corp. will post ($3.05) earnings per share for the current year.
In related news, CEO Jeffrey W. Albers sold 17,000 shares of the business’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $22.86, for a total transaction of $388,620.00. Following the transaction, the chief executive officer now owns 76,494 shares of the company’s stock, valued at $1,748,652.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.93% of the company’s stock.
A number of institutional investors have recently made changes to their positions in BPMC. BlackRock Group LTD raised its position in shares of Blueprint Medicines Corp. by 160.8% in the second quarter. BlackRock Group LTD now owns 6,992 shares of the company’s stock worth $141,000 after buying an additional 4,311 shares during the period. BlackRock Advisors LLC raised its position in shares of Blueprint Medicines Corp. by 96.1% in the second quarter. BlackRock Advisors LLC now owns 8,245 shares of the company’s stock worth $167,000 after buying an additional 4,040 shares during the period. American International Group Inc. raised its position in shares of Blueprint Medicines Corp. by 110.0% in the second quarter. American International Group Inc. now owns 11,520 shares of the company’s stock worth $233,000 after buying an additional 6,034 shares during the period. Nationwide Fund Advisors raised its position in shares of Blueprint Medicines Corp. by 114.0% in the second quarter. Nationwide Fund Advisors now owns 12,969 shares of the company’s stock worth $263,000 after buying an additional 6,909 shares during the period. Finally, Fernwood Investment Management LLC bought a new position in shares of Blueprint Medicines Corp. during the second quarter worth about $285,000. 73.65% of the stock is currently owned by institutional investors and hedge funds.
About Blueprint Medicines Corp.
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp. and related companies with MarketBeat.com's FREE daily email newsletter.